Supporting drug development and clinical research through specialist biomarker insights.
At the core of ProAxsis’ scientific offering is its proprietary ProteaseTag® technology.
ProteaseTag® smart molecules are designed to selectively and irreversibly bind active proteases, enabling the measurement and analysis of active protease biomarkers across a range of research applications.
This patented technology underpins ProAxsis’ portfolio of research-use assays and specialist biomarker solutions, supporting pharmaceutical and clinical research partners involved in respiratory disease, inflammation and other protease associated conditions.
ProAxsis focuses on the measurement of active protease biomarkers of disease, and supports pharmaceutical, biotech and research organisations through:
The company combines deep scientific expertise with proprietary technology to support drug development, translational research and clinical trial programmes, particularly in respiratory disease.
With capabilities spanning research-use assay products, specialist sample testing and bespoke scientific collaboration, ProAxsis delivers high-quality biomarker insight designed to support more effective research and development programmes.
ProAxsis has developed a range of research-use immunoassays and a point-of-use test incorporating patented technology, including:
ProAxsis’ specialist protease biomarker expertise supports pharmaceutical, biotechnology and academic research programmes.
Our integrated offering includes:
ProAxsis products and services support research and clinical trials for chronic lung diseases such as:
Interested in learning more? Get in touch.